Therapeutic use of Tadekinig alfa in NLRC4 mutation and XIAP deficiency

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

6 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This is a clinical trial to study the use of Tadekinig alfa or placebo (medication) in the treatment of NLRC4 MAS mutation or XIAP deficiency. This study involves taking the medication every 48 hours for up to 26 weeks. Participants will also be required to attend up to 14 in-person study visits to review their disease state while they are taking the medication. Compensation for time and travel related to study visits may be provided to qualified participants.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at rrc [at] chop.edu or 267-426-8726.

Eligibility & Criteria

IRB #:
17-013986
Official Title:
Multicenter Double-Blind, Placebo-Controlled, Randomized Withdrawal Trial With Tadekinig alfa (r-hIL-18BP) in Patients with IL-18 Driven Monogenic Auto-Inflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Study Phase:
Phase III
Eligible Age Range:
1 Month - 17 Years
Gender:
All
Study Categories:
Leader
Edward M. Behrens

Edward M. Behrens, MD